Literature DB >> 22508762

Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma.

Derek R Johnson1, Allison M Sawyer, Christina A Meyers, Brian Patrick O'Neill, Jeffrey S Wefel.   

Abstract

Cognitive dysfunction is a common manifestation of primary brain tumors. We evaluated the association between early cognitive dysfunction and prognosis in a cohort of patients with newly diagnosed glioblastoma. Ninety-one patients who completed neuropsychological assessment after tumor resection but before further treatment were identified in the MD Anderson Neuropsychology database. The relationship between performance on cognitive testing and survival was evaluated using not only Cox proportional hazards models that included clinical factors such as age and KPS but also the Kaplan-Meier method. Median survival time from surgery was 20.7 months. Rates of impairment on cognitive testing ranged from 7.1% for Similarities, to 60.0% for Hopkins Verbal Learning Test-Revised Total Recall. As continuous variables, the Clinical Trial Battery Composite, Trail Making Test Part B, and Controlled Oral Word Association test were associated with survival. Impairment on the Trail Making Test Part B, Controlled Oral Word Association, Similarities, and Digit Span were associated with mortality. Kaplan-Meier analysis demonstrated the survival impact of these tests on the group as a whole and in select patient subgroups defined by classification by the Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA). Cognitive impairment as measured by specific neuropsychological tests is independently associated with poor prognosis in patients with newly diagnosed glioblastoma, and this effect remains significant even within patient subgroups defined by RTOG RPA class. Executive function and attention are the cognitive domains most closely associated with prognosis in this analysis.

Entities:  

Mesh:

Year:  2012        PMID: 22508762      PMCID: PMC3367851          DOI: 10.1093/neuonc/nos082

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  26 in total

1.  Trail Making Test A and B: normative data stratified by age and education.

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2004-03       Impact factor: 2.813

2.  Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Authors:  Jeffrey S Wefel; Timothy Cloughesy; James L Zazzali; Maoxia Zheng; Michael Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Asha Das; Henry S Friedman
Journal:  Neuro Oncol       Date:  2011-05-09       Impact factor: 12.300

3.  Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

Authors:  Emily Ruden; David A Reardon; April D Coan; James E Herndon; Whitney E Hornsby; Miranda West; Diane R Fels; Annick Desjardins; James J Vredenburgh; Emily Waner; Allan H Friedman; Henry S Friedman; Katherine B Peters; Lee W Jones
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

Review 4.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

Authors:  M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs
Journal:  Lancet Oncol       Date:  2011-04-05       Impact factor: 41.316

5.  Volumetric measurement of brain tumors from MR imaging.

Authors:  W M Shi; D M Wildrick; R Sawaya
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

6.  Neuropsychological deficits in symptomatic minor head injury patients after concussion and mild concussion.

Authors:  B E Leininger; S E Gramling; A D Farrell; J S Kreutzer; E A Peck
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

7.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

8.  Application of the Trail Making Test in differentiating neuropsychological impairment of elderly persons.

Authors:  C L Greenlief; R B Margolis; G J Erker
Journal:  Percept Mot Skills       Date:  1985-12

9.  Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC.

Authors:  A M Stark; W Stepper; H M Mehdorn
Journal:  Eur J Cancer Care (Engl)       Date:  2009-11-11       Impact factor: 2.520

10.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Authors:  Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more
  38 in total

Review 1.  Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients.

Authors:  Christina K Cramer; Tiffany L Cummings; Rachel N Andrews; Roy Strowd; Stephen R Rapp; Edward G Shaw; Michael D Chan; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2019-04-08

2.  Genetic Modulation of Neurocognitive Function in Glioma Patients.

Authors:  Yanhong Liu; Renke Zhou; Erik P Sulman; Michael E Scheurer; Nicholas Boehling; Georgina N Armstrong; Spiridon Tsavachidis; Fu-Wen Liang; Carol J Etzel; Charles A Conrad; Mark R Gilbert; Terri S Armstrong; Melissa L Bondy; Jeffrey S Wefel
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

3.  The association between cognitive functioning and health-related quality of life in low-grade glioma patients.

Authors:  Florien W Boele; Maaike Zant; Emma C E Heine; Neil K Aaronson; Martin J B Taphoorn; Jaap C Reijneveld; Tjeerd J Postma; Jan J Heimans; Martin Klein
Journal:  Neurooncol Pract       Date:  2014-05-06

4.  Neurocognitive functioning and quality of life in patients with recurrent malignant gliomas treated on a phase Ib trial evaluating topotecan by convection-enhanced delivery.

Authors:  Jennifer A Oberg; Amie N Dave; Jeffrey N Bruce; Stephen A Sands
Journal:  Neurooncol Pract       Date:  2014-09

Review 5.  The quality of measurement properties of neurocognitive assessment in brain tumor clinical trials over the last 30 years: a COSMIN checklist-based approach.

Authors:  Maria De Martino; Barbara Santini; Giovanna Cappelletti; Annapina Mazzotta; Matteo Rasi; Giorgia Bulgarelli; Luciano Annicchiarico; Alessandro Marcocci; Andrea Talacchi
Journal:  Neurol Sci       Date:  2020-07-12       Impact factor: 3.307

6.  Hypoxia-induced EPHB2 promotes invasive potential of glioblastoma.

Authors:  Wenjin Qiu; Shibin Song; Wei Chen; Jiale Zhang; Hua Yang; Yimin Chen
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

Review 7.  Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Authors:  Jaishri O Blakeley; Stephen Joel Coons; John R Corboy; Nancy Kline Leidy; Tito R Mendoza; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

8.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.

Authors:  Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner
Journal:  Neuro Oncol       Date:  2013-08-16       Impact factor: 12.300

Review 9.  Symptom management and quality of life in glioma patients.

Authors:  Florien W Boele; Martin Klein; Jaap C Reijneveld; Irma M Verdonck-de Leeuw; Jan J Heimans
Journal:  CNS Oncol       Date:  2014-01

Review 10.  Relationship between cognitive function and prognosis in glioblastoma.

Authors:  Derek R Johnson; Jeffrey S Wefel
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.